Journal
JOURNAL OF IMMUNOLOGY
Volume 178, Issue 8, Pages 4731-4735Publisher
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.178.8.4731
Keywords
-
Categories
Funding
- NICHD NIH HHS [K08 HD051584-02, K08 HD051584, K08 HD051584-01, K08 HD051584-03, K08HD51584, R01HD018184] Funding Source: Medline
Ask authors/readers for more resources
The vast majority of the world's population is infected with HSV. Although antiviral therapy can reduce the incidence of reactivation and asymptomatic viral shedding, and limit morbidity and mortality from active disease, it cannot cure infection. Therefore, the development of an effective vaccine is an important global health priority. In this study, we demonstrate that recombinant Listeria monocytogenes (Lm) expressing the H-2K(b) glycoprotein B (gB)(498-505) peptide from HSV-1 triggers a robust CD8 T cell response to this Ag resulting in protective immunity to HSV infection. Following challenge with HSV-1, immune-competent mice primed with recombinant Lm-expressing gB(498-505) Ag were protected from HSV-induced paralysis. Protection was associated with dramatic reductions in recoverable virus, and early expansion of HSV-1-specific CD8 T cells in the regional lymph nodes. Thus, recombinant Lm-expressing Ag from HSV represents a promising new class of vaccines against HSV infection.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available